摘要
目的:探讨骨质疏松疼痛患者应用仙灵骨葆胶囊治疗临床疗效分析及其安全性评价,为临床治疗提供依据。方法:将2012年3月—2014年3月期间本院160例骨质疏松疼痛患者根据随机数字表法随机分为治疗组(n=80)和对照组(n=80);对照组口服钙尔奇治疗,治疗组口服仙灵骨葆胶囊治疗,两组患者均以6周为1个疗程,2个疗程结束后分析其临床疗效、骨密度、血中骨指标以及不良反应。结果:治疗组治疗2个疗程后总有效率(91.25%)显著高于对照组(77.50%),且有显著性差异(P<0.05);治疗组治疗后腰椎BMD较治疗前明显增加,且有显著性差异(P<0.05);治疗组治疗后腰椎BMD明显高于对照组治疗后,且有显著性差异(P<0.05);治疗组治疗后骨钙素、β-胶原系列与治疗前比较差异具有统计学意义(P<0.05);治疗组治疗后骨钙素明显高于对照组治疗后,且有显著性差异(P<0.05);治疗组治疗后β-胶原系列明显低于对照组治疗后,且有显著性差异(P<0.05);两组患者均未发生明显的不良反应。结论:骨质疏松疼痛患者应用仙灵骨葆胶囊治疗临床疗效显著,可明显缓解患者疼痛,增加其骨钙素含量及骨密度,且无明显不良反应,临床上应用安全可靠,值得进一步研究推广。
Objective： To investigate the clinical efficacy and safety evaluation of Xianling Gubao capsules on osteoporosis and to provide the basis for clinical treatment. Methods： During March 2012- March 2014 in our hospital,160 cases of osteoporosis pain patients were randomly divided into treatment groups based on a random number table（ n = 80） and control group（ n = 80）. The control group was treated with Caltrate and the treatment group was treated with Xianling Gubao Capsule. Both groups were treated for six weeks as a course of treatment and after two course,we analyzed its clinical efficacy,bone density,blood and bone indicators of adverse reactions. Results： After treatment,lumbar spine BMD increased significantly and there was significant difference（ P〈0. 05）. After treatment,lumbar spine BMD was significantly higher after treatment and there was significant difference（ P〈0. 05）. After treatment,osteocalcin and β- collagen difference was statistically significant（ P〈0. 05）. The osteocalcin after treatment was significantly higher and there was significant difference（ P〈0. 05）. After treatment,β- collagen series were significantly lower than that of the control group after treatment and there was significant difference（ P〈0. 05）. Two groups had no significant adverse reactions. Conclusion： Xianling Gubao capsule has significant clinical effect on patients with osteoporosis pain and can significantly relieve pain in patients and increase their osteocalcin levels and has no significant adverse reactions. The clinical application is safe,reliable and worthy of further research and promotion.
出处
《中华中医药学刊》
CAS
2014年第12期3050-3052,共3页
Chinese Archives of Traditional Chinese Medicine
